CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Interest Expense

Cost of servicing the company's debt during the period.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Interest expense amounts to 0.0% of revenue for CAMP, versus a peer median of 0.0%.
CAMP Competitors
Interest Expense for CAMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$2.33M USD-26.3%+29.3%0.9%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$1.53M USD-10.6%+88.8%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$55K USD-16.7%+127.9%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$1.94K CAD-84.1%-51.1%0.0%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$0 USD——0.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD———
ATYRaTyr Pharma, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CAMP) —-21.5%+59.1%0.0%

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Nov 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.84M0350K652K3.5M
Cost of Revenue173.95M0001.64M
Gross Profit121.89M(947K)350K652K1.86M
Gross Margin41.2%—100.0%100.0%53.1%
Research & Development28.44M34.77M40.62M38.82M38.2M
Selling, General & Admin100.9M10.23M11.61M14.92M17.36M
Operating Expenses134.76M45M52.23M53.74M53.92M
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
EBITDA7.49M(44.12M)(50.2M)(51.39M)(50.42M)
EBITDA Margin2.5%—-14343.1%-7882.2%-1441.5%
Operating Income(15.31M)(45M)(51.88M)(53.09M)(52.06M)
Operating Margin-5.2%—-14822.6%-8142.3%-1488.3%
Interest Income002.81M1.33M2.17M
Interest Expense15.32M6.26M000
Other Income / Expenses(14.75M)809K2.59M1.3M(28.34M)
Income Before Tax(30.06M)(44.19M)(49.29M)(51.79M)(80.4M)
Pre-Tax Margin-10.2%—-14083.1%-7943.4%-2298.5%
Income Tax Expense1.09M0000
Net Income(31.15M)(44.19M)(49.29M)(51.79M)(80.4M)
Net Margin-10.5%—-14083.1%-7943.4%-2298.5%
EPS (Basic)(0.88)(0.90)(4.07)(2.66)(2.65)
EPS (Diluted)(0.88)(0.90)(4.07)(2.66)(2.65)
Weighted Avg Shares35.25M36.1M12.12M19.51M30.38M
Weighted Avg Shares (Diluted)35.25M36.13M12.12M19.51M30.38M

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.